Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (NASDAQ: VERA) announced inducement grants approved by its Compensation Committee on December 3, 2024. The grants, awarded to seventeen new employees, include non-qualified stock options to purchase 171,750 shares of Class A common stock at $49.38 per share and restricted stock units (RSUs) for 86,625 shares.
The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting February 20, 2025. Both grants are subject to continued employment with Vera and were made under the Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (NASDAQ: VERA) ha annunciato concessioni di incentivo approvate dal suo Comitato Compensazioni il 3 dicembre 2024. Le concessioni, assegnate a diciassette nuovi dipendenti, includono opzioni su azioni non qualificate per acquistare 171.750 azioni di azioni ordinarie di Classe A a 49,38 $ per azione e unità di azioni vincolate (RSU) per 86.625 azioni.
Le opzioni su azioni matureranno in quattro anni, con il 25% che matura nel primo anniversario e il resto che matura mensilmente per 36 mesi. Le RSU matureranno in quattro anni, con il 25% che matura annualmente a partire dal 20 febbraio 2025. Entrambe le concessioni sono soggette a un'occupazione continuativa con Vera e sono state effettuate ai sensi del Piano di Incentivo in conformità con la Regola di quotazione Nasdaq 5635(c)(4).
Vera Therapeutics (NASDAQ: VERA) anunció concesiones de incentivo aprobadas por su Comité de Compensación el 3 de diciembre de 2024. Las concesiones, otorgadas a diecisiete nuevos empleados, incluyen opciones de acciones no calificadas para comprar 171,750 acciones de acciones ordinarias de Clase A a 49.38 $ por acción y unidades de acciones restringidas (RSU) para 86,625 acciones.
Las opciones de acciones se consolidarán durante cuatro años, con el 25% consolidándose en el primer aniversario y el resto consolidándose mensualmente durante 36 meses. Las RSU se consolidarán durante cuatro años, con el 25% consolidándose anualmente a partir del 20 de febrero de 2025. Ambas concesiones están sujetas a la continuación del empleo con Vera y se realizaron bajo el Plan de Incentivo de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4).
베라 테라퓨틱스 (NASDAQ: VERA)는 2024년 12월 3일 보상위원회에서 승인한 유도 보상을 발표했습니다. 이 보상은 17명의 신입직원에게 수여되며, 주식의 비자격 옵션을 포함하여 클래스 A 보통주 171,750주를 주당 49.38달러에 구매할 수 있으며, 86,625주의 제한된 주식 단위(RSU)를 포함합니다.
주식 옵션은 4년 동안 분할 지급되며, 첫 번째 기념일에 25%가 지급되고 나머지는 36개월 동안 매달 지급됩니다. RSU는 4년 동안 분할 지급되며, 2025년 2월 20일부터 매년 25%가 지급됩니다. 두 가지 보상 모두 베라와의 지속적인 고용에 따라 달라지며, Nasdaq 상장 규칙 5635(c)(4)에 따라 유도 계획 하에 이루어졌습니다.
Vera Therapeutics (NASDAQ: VERA) a annoncé des octrois d'incitation approuvés par son Comité de rémunération le 3 décembre 2024. Les octrois, accordés à dix-sept nouveaux employés, incluent des options d'achat d'actions non qualifiées pour acquérir 171 750 actions ordinaires de classe A au prix de 49,38 $ par action, ainsi que des unités d'actions restreintes (RSU) pour 86 625 actions.
Les options sur actions seront acquises sur une période de quatre ans, avec 25% acquises lors du premier anniversaire et le reste acquis mensuellement sur 36 mois. Les RSU seront acquises sur quatre ans, avec 25% acquises annuellement à partir du 20 février 2025. Les deux octrois sont soumis à une continuité d'emploi avec Vera et ont été effectués dans le cadre du Plan d'incitation conformément à la règle de cotation Nasdaq 5635(c)(4).
Vera Therapeutics (NASDAQ: VERA) hat am 3. Dezember 2024 durch seinen Vergütungsausschuss genehmigte Incentive-Zuwendungen angekündigt. Die Zuwendungen, die an siebzehn neue Mitarbeiter vergeben wurden, beinhalten nicht qualifizierte Aktienoptionen zum Kauf von 171.750 Aktien der Stammaktien der Klasse A zu je 49,38 $ pro Aktie sowie Restricted Stock Units (RSUs) für 86.625 Aktien.
Die Aktienoptionen werden über vier Jahre gestaffelt, wobei 25% am ersten Jahrestag und der Rest monatlich über 36 Monate fällig wird. Die RSUs werden über vier Jahre festgelegt, wobei 25% jährlich ab dem 20. Februar 2025 fällig werden. Beide Zuwendungen sind an eine fortdauernde Beschäftigung bei Vera gebunden und wurden im Rahmen des Incentive-Plans gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- Company demonstrates ability to attract new talent with competitive equity compensation
- Stock price of $49.38 per share indicates strong market valuation
- Equity grants will result in shareholder dilution
- Significant compensation expenses from new hires will impact operating costs
BRISBANE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 171,750 shares of Class A common stock and restricted stock units (RSUs) for 86,625 shares of Class A common stock to seventeen new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on December 3, 2024 has an exercise price per share equal to
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
What inducement grants did Vera Therapeutics (VERA) announce on December 9, 2024?
What is the vesting schedule for VERA's December 2024 inducement grants?
What was the exercise price for VERA's stock options granted on December 3, 2024?
